Deflazacort helps to maintain both muscle and pulmonary function in Duchenne muscular dystrophy

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1275, 2001-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deflazacort/prednisone: Growth failure and delayed bone maturation and puberty in patients with Duchenne muscular dystrophy: 4 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1413, 2012-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod   Rodino-Klapac Louise R.   Mendell Jerry R  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

By Judge Daniel P.   Kass David A.   Thompson W. Reid   Wagner Kathryn R.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite

Duchenne muscular dystrophy drug discovery – the application of utrophin promoter activation screening

By Moorwood Catherine   Khurana Tejvir S  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 5, 2013-06 ,pp. : 569-581

Informa Healthcare

Access to resources Recommend Favorite

Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

By  

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 110-121

Bentham Science Publishers

Access to resources Recommend Favorite